EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudieVergleichsstudie

Fourteen‐and Ten‐Day Tegoprazan–Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication—A Noninferiority, Multicenter, Randomized Controlled Trial

Yan Fan, Chuanfei Li, Wenguang Zhang, Jinlian Shi, Renzheng Liang, Meng Deng, Shengtao Liao, Xiao Xiao, Ke Zhan, Liewang Qiu, Zhechuan Mei, Lin Lv iD

Journal of Gastroenterology and Hepatology · 2026

DOI: 10.1111/jgh.70180 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Yan Fan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Amoxicillin, Helicobacter pylori, Bismuth. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Chongqing Science and Health Joint Medical Research Project, Doctoral "Through Train" Research Program of Chongqing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Tegoprazan has shown great potential in the eradication of Helicobacter pylori infection. This study aims to evaluate the efficacy and safety of Tegoprazan‐based dual therapy for H. pylori eradication.

Methods

This was a noninferiority, multicenter, randomized controlled trial in China. Subjects were randomly assigned to three groups: the 14‐THA group, the 10‐THA group (Tegoprazan 50 mg twice/day, Amoxicillin 1 g 3 times/day, for 14 and 10 days), and the B‐quadruple group (esomeprazole 20 mg, bismuth 220 mg, Amoxicillin 1 g, twice/day, tetracycline 0.5 g 3 times/day, for 14 days). The three groups' eradication rates, adverse events, and compliance were compared.

Results

A total of 228 individuals were included in the randomization. According to the per‐protocol analysis (PP), modified intention‐to‐treat (MITT) analysis, and intention‐to‐treat (ITT) analysis, there was no statistically significant difference between the 14‐THA group and B‐quadruple group (PP: 90.3% vs. 91.8%, MITT: 84.8% vs. 90.5%, ITT: 73.7% vs. 75.0%, p > 0.05). However, the 10‐THA group has a lower eradication rate than the B‐quadruple group (PP: 67.2% vs. 91.8%, MITT: 64.1% vs. 90.5%, ITT: 53.9% vs. 75.0%, p < 0.05). Additionally, the efficacy of the 14‐THA group was not inferior to that of the B‐quadruple group in PP ( p = 0.0488). Adverse events and compliance rates did not differ among the three groups ( p > 0.05).

Conclusion

The eradication rate of the 14‐THA group is > 90%, which is not inferior to the current bismuth‐containing quadruple regimen, with a favorable safety profile. However, the efficacy of the 10‐THA dual therapy is unacceptable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsAmoxicillinHelicobacter pyloriBismuthAnti-Bacterial AgentsEsomeprazoleProton Pump InhibitorsHumansMaleFemaleMiddle AgedDrug Therapy, CombinationTreatment OutcomeAdultDrug Administration ScheduleTetracyclineTime FactorsAgedChina

Stichwörter der Autor:innen

H. pyloridual therapyeradicationtegoprazan

Substanzen

AmoxicillinBismuthAnti-Bacterial AgentsEsomeprazoleTetracyclineProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Gastroenterology, People's Hospital of Chongqing Banan District, Chongqing, China.
  • Department of Gastroenterology, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Gastroenterology, The Thirteenth People's Hospital of Chongqing, Chongqing, China.
  • Department of Gastroenterology, People's Hospital of Chongqing Shizhu Tujia Autonomous County, Chongqing, China.
  • Department of Gastroenterology, Chongqing Emergency Medical Center, Chongqing, China.

ORCID-Profile: Lin Lv

Förderung

  • Chongqing Science and Health Joint Medical Research Project
  • Doctoral "Through Train" Research Program of Chongqing, China

Zitieren

APA

Fan, Y., Li, C., Zhang, W., Shi, J., Liang, R., Deng, M., Liao, S., Xiao, X., Zhan, K., Qiu, L., Mei, Z., & Lv, L. (2026). Fourteen‐and Ten‐Day Tegoprazan–Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication—A Noninferiority, Multicenter, Randomized Controlled Trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70180

Vancouver

Fan Y, Li C, Zhang W, Shi J, Liang R, Deng M, et al. Fourteen‐and Ten‐Day Tegoprazan–Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication—A Noninferiority, Multicenter, Randomized Controlled Trial. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70180

BibTeX
@article{Fan2026,
  author = {Fan, Yan and Li, Chuanfei and Zhang, Wenguang and Shi, Jinlian and Liang, Renzheng and Deng, Meng and Liao, Shengtao and Xiao, Xiao and Zhan, Ke and Qiu, Liewang and Mei, Zhechuan and Lv, Lin},
  title = {Fourteen‐and Ten‐Day Tegoprazan–Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for Helicobacter pylori Eradication—A Noninferiority, Multicenter, Randomized Controlled Trial},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1111/jgh.70180}
}
Kostenlos starten →